A large-scale retrospective cohort study, released by The Journal of Allergy and Clinical Immunology in 2025, explored the risk of new-onset type 2 inflammatory diseases after COVID-19 infection and vaccination. Using electronic health records from more than 118 million US patients, researchers found that COVID-19 infection significantly increased the risk of new-onset asthma, allergic rhinitis, and chronic rhinosinusitis, while showing no impact on atopic dermatitis or eosinophilic esophagitis. In contrast, COVID-19 vaccination has been shown to lower the risks of asthma and chronic rhinosinusitis. This study suggests that the COVID-19 infection is associated with a heightened risk of respiratory type 2 inflammatory diseases, while the COVID-19 vaccination appears to be a protective factor.
Read the full research study here.
Read the news article here.